Go Deep
WuXi Biologics (Cayman) Inc.
WuXi Biologics (Cayman) Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,373 | 36.2 | 3.58 | 0.05 | 581.73 |
| Oct 2026 | 20,375 | 36.2 | 3.58 | 0.05 | 582.36 |
| Oct 2026 | 20,147 | 36.3 | 3.71 | 0.05 | 604.71 |
| Oct 2026 | 20,227 | 37.7 | 3.66 | 0.05 | 595.37 |
| Oct 2026 | 20,651 | 37.1 | 3.35 | 0.05 | 544.51 |
| Oct 2026 | 20,587 | 34.2 | 3.40 | 0.05 | 553.62 |
WuXi Biologics (Cayman) Inc. Quarterly Results
Quarterly data isn't available for this company right now.
WuXi Biologics (Cayman) Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 21,790,018,000.0 | 18,675,371,000.0 | 17,034,255,000.0 | 15,268,660,000.0 |
| Net Profit | 4,908,343,000.0 | 3,356,081,000.0 | 3,399,729,000.0 | 4,420,286,000.0 |
| EPS | 1.2 | 0.8 | 0.8 | 1.1 |
WuXi Biologics (Cayman) Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 63,696,738,000.0 | 56,977,435,000.0 | 56,575,726,000.0 | 49,564,385,000.0 | — |
| Total Liabilities | 10,657,394,000.0 | 11,499,866,000.0 | 12,557,844,000.0 | 13,351,308,000.0 | — |
| Total Equity | 47,248,676,000.0 | 41,819,209,000.0 | 40,331,597,000.0 | 35,047,407,000.0 | — |
Owes vs Owns
WuXi Biologics (Cayman) Inc. owed ¥0.17 for every ¥1 it owned in Dec 2025, down from ¥0.27 in Dec 2022.
| Period | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Owes vs Owns | 0.17× | 0.20× | 0.22× | 0.27× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
WuXi Biologics (Cayman) Inc. Assets & Liabilities Breakdown (CNY millions)
What it owns — Dec 2025
Cash & short-term investments 24.7%Receivables 12.0%Inventory 2.2%Fixed assets (tangible) 46.7%Intangible assets 3.1%Long-term investments 5.0%Other assets 6.3%
How it's funded — Dec 2025
Short-term debt 1.4%Payables 1.7%Other liabilities 13.4%Shareholders' equity 83.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 15,732.8 | 10,709.8 | 11,243.4 | 8,714.3 |
| Receivables | 7,646.6 | 5,515.4 | 5,653.6 | 4,650.7 |
| Inventory | 1,381.3 | 1,521.7 | 1,765.8 | 2,280.9 |
| Fixed assets (tangible) | 29,754.0 | 28,435.4 | 29,939.5 | 25,916.0 |
| Intangible assets | 1,997.1 | 1,972.3 | 2,041.7 | 2,078.7 |
| Long-term investments | 3,202.8 | 1,266.6 | 1,393.5 | 1,581.6 |
| Other assets | 3,982.2 | 7,556.3 | 4,538.2 | 4,342.2 |
| Liabilities & equity | ||||
| Short-term debt | 873.5 | 2,435.3 | 576.3 | 1,321.4 |
| Long-term debt | 169.4 | 200.9 | 1,571.0 | 1,461.6 |
| Payables | 1,091.5 | 747.1 | 833.3 | 794.4 |
| Other liabilities | 8,523.0 | 8,116.5 | 9,577.2 | 9,773.9 |
| Shareholders' equity | 53,039.3 | 45,477.6 | 44,017.9 | 36,213.1 |
| Net tangible assets | 45,251.6 | 39,846.9 | 38,289.8 | 32,968.7 |
WuXi Biologics (Cayman) Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 6,340,922,000.0 | 5,217,257,000.0 | 4,667,712,000.0 | 5,541,673,000.0 | — |
| Investing Activities | -3,087,142,000.0 | -3,941,706,000.0 | -3,228,266,000.0 | -5,908,252,000.0 | — |
| Financing Activities | -2,163,968,000.0 | -2,750,191,000.0 | 1,961,163,000.0 | -2,591,592,000.0 | — |